Some ancestral rodents likely had repeated infections with SARS-like coronaviruses, leading them to acquire tolerance or resistance to the pathogens, according to new research in PLOS Computational Biology by Sean King and Mona Singh of Princeton University.
This raises the possibility that modern rodents may be reservoirs of SARS-like viruses, the researchers say.
SARS-CoV-2, the virus that causes COVID-19 infection, is of zoonotic origin—it jumped from a non-human animal to humans. Previous research has shown that Chinese Horseshoe bats are a host of numerous SARS-like viruses and tolerate these viruses without extreme symptoms. Identifying other animals that have adapted tolerance mechanisms to coronaviruses is important for awareness of potential viral reservoirs that can spread new pathogens to humans.
In the new research, King and Singh performed an evolutionary analysis, across mammalian species, of the ACE2 receptors, used by SARS viruses to gain entry into mammalian cells. Primates had highly conserved sequences of amino acids in the sites of the ACE2 receptor known to bind SARS viruses. Rodents, however, had a greater diversity — and an accelerated rate of evolution — in these spots. Overall, the results indicated that SARS-like infections have not been evolutionary drivers in primate history, but that some rodent species have likely been exposed to repeated SARS-like coronavirus infections for a considerable evolutionary period.
“Our study suggests that ancestral rodents may have had repeated infections with SARS-like coronaviruses and have acquired some form of tolerance or resistance to SARS-like coronaviruses as a result of these infections,” the authors add. “This raises the tantalizing possibility that some modern rodent species may be asymptomatic carriers of SARS-like coronaviruses, including those that may not have been discovered yet.”
Go To Source For Respiratory Therapy Coverage
RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry.